The COVID-19 pandemic has put the pharma and biotech industries once again at the forefront of leading the world’s efforts to fight back against another insidious threat. Here at CherryCircle Software, it has ignited our team to fulfil our mission to help in this fight by bringing industry-leading software solutions to bear on the significant process development and manufacturing challenges ahead.
These past two quarters have been some of our busiest as we continue to onboard new customers, partners, and employees, while working to establish best practices in knowledge and quality risk management during process development and validation. Our team has been intensely focused as we work with customers developing biologics, cell and gene-based therapies, and biosimilars, and with regulatory agencies considering how to assess process understanding and product quality going forward. Now, more than ever, our leadership on these topics of discussion matters.
We are thrilled to announce the latest release of QbDVision titled, Disco. Our teams have been hard at work at bringing the latest and greatest tools to further automate and simplify your knowledge and quality risk management activities. The release is packed with new capabilities and is one of our largest to date. You’ll find the details below or contact us to learn more.
We also expanded our team this year focusing specifically on client services and building long-term relationships with our customers. We have recruited personnel with extensive backgrounds in pharmaceutical and biotech manufacturing processes and holistic quality-by-design principles to help our customers quickly integrate QbDVision into their operations.
Finally, at the end of February, we were invited to present at the IFPAC 2020 alongside other participants from Amgen, Eli Lilly, Biogen, Emerson, and Merck as well as representatives from the FDA. One of the key takeaways from the session was that shift toward structured data is inevitable, and it will be critical to reducing the inefficiencies with today’s document-heavy focus on managing process development and validation.
As we look ahead, we are excited to work alongside our customers as they deal with the new challenges facing them. Supply chains have been disrupted, geopolitical risks are igniting discussions about onshoring vs. offshoring manufacturing activities, and resources are being mobilized to address the current and future threats to our well-being. We’ll be hard at work on our mission and we are ready to support you on yours.
This article was written by Medilink EM Member. QbDVision Ltd.
